Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ArriVent BioPharma, Inc. before investing.

In this article, we go over a few key elements for understanding ArriVent BioPharma, Inc.’s stock price such as:

• ArriVent BioPharma, Inc.’s current stock price and volume
• Why ArriVent BioPharma, Inc.’s stock price changed recently
• Upgrades and downgrades for AVBP from analysts
• AVBP’s stock price momentum as measured by its relative strength

About ArriVent BioPharma, Inc. (AVBP)

Before we jump into ArriVent BioPharma, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Want to learn more about ArriVent BioPharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ArriVent BioPharma, Inc..

ArriVent BioPharma, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, ArriVent BioPharma, Inc.’s stock price was $29.820.

ArriVent BioPharma, Inc. is down 2.74% from its previous closing price of $30.660.

During the last market session, ArriVent BioPharma, Inc.’s stock traded between $29.670 and $32.650. Currently, there are approximately 45.07 million shares outstanding for ArriVent BioPharma, Inc..

ArriVent BioPharma, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

ArriVent BioPharma, Inc. Stock Price History

ArriVent BioPharma, Inc.’s (AVBP) price is currently down 14.16% so far this month.

During the month of July, ArriVent BioPharma, Inc.’s stock price has reached a high of $35.600 and a low of $27.400.

Over the last year, ArriVent BioPharma, Inc. has hit prices as high as $35.830 and as low as $16.100. Year to date, ArriVent BioPharma, Inc.’s stock is up 48.21%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ArriVent BioPharma, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 2 analysts who downgraded ArriVent BioPharma, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate ArriVent BioPharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ArriVent BioPharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ArriVent BioPharma, Inc. (AVBP) by visiting AAII Stock Evaluator.

Relative Price Strength of ArriVent BioPharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, ArriVent BioPharma, Inc. has a weighted four-quarter relative price strength of 5.51%, which translates to a Momentum Score of 72 and is considered to be Strong.

Want to learn more about how ArriVent BioPharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ArriVent BioPharma, Inc. Stock Price: Bottom Line

As of July 31, 2026, ArriVent BioPharma, Inc.’s stock price is $29.820, which is down 2.74% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ArriVent BioPharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.